• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全身免疫炎症指数是预测肺癌生存率的一种有前景的非侵入性标志物:一项荟萃分析。

Systemic immune-inflammation index is a promising noninvasive marker to predict survival of lung cancer: A meta-analysis.

作者信息

Zhang Yi, Chen Bo, Wang Lijuan, Wang Rong, Yang Xianjin

机构信息

Department of General Surgery.

Department of Cardiology, the First People's Hospital of Neijiang, Neijiang, Sichuan Province.

出版信息

Medicine (Baltimore). 2019 Jan;98(3):e13788. doi: 10.1097/MD.0000000000013788.

DOI:10.1097/MD.0000000000013788
PMID:30653090
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6370019/
Abstract

BACKGROUND

The prognostic value of pretreatment systemic immune-inflammation index (SII) in lung cancer has yet to be fully established.

METHODS

Relevant articles were obtained by performing a systematic search. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were used to assess the relationship between SII index and overall survival (OS) in lung cancer; the OS was calculated from the time of cancer diagnosis to the date of death due to any cause or to the last date of follow-up.

RESULTS

In total, 2786 patients with lung cancer from 7 studies were included in this meta-analysis. The median thresholds to define high SII was 640 (range 395.4-1600) in the analyzed studies. The pooled HR for OS was 1.77 (95% CI: 1.54-2.00, P < .001), suggesting that the patients with a high SII score had a worse OS. In addition, results from subgroup meta-analysis showed the significant prognostic significance of SII in lung cancer. Especially, the predictive value of SII was significant in the multivariable model for NSCLC (HR: 1.97, 95% CI: 1.69-2.25, P < .001; 5 studies, 1746 patients), and SCLC (HR: 1.38, 95% CI: 1.02-1.85, P < .001; 1 study, 919 patients).

CONCLUSION

Our data suggest that high SII index indicates poor survival rate in lung cancer. Further researches are warranted to verify the significance of SII index in clinical practice.

摘要

背景

肺癌患者治疗前的全身免疫炎症指数(SII)的预后价值尚未完全明确。

方法

通过系统检索获取相关文章。采用风险比(HR)和95%置信区间(95%CI)评估SII指数与肺癌患者总生存期(OS)之间的关系;OS从癌症诊断时间计算至因任何原因死亡日期或最后随访日期。

结果

本荟萃分析共纳入来自7项研究的2786例肺癌患者。分析的研究中定义高SII的中位数阈值为640(范围395.4 - 1600)。OS的合并HR为1.77(95%CI:1.54 - 2.00,P <.001),表明SII评分高的患者OS较差。此外,亚组荟萃分析结果显示SII在肺癌中具有显著的预后意义。特别是,SII在非小细胞肺癌(NSCLC)多变量模型中的预测价值显著(HR:1.97,95%CI:1.69 - 2.25,P <.001;5项研究,1746例患者),在小细胞肺癌(SCLC)中也显著(HR:1.38,95%CI:1.02 - 1.85,P <.001;1项研究,919例患者)。

结论

我们的数据表明,高SII指数表明肺癌患者生存率低。有必要进一步研究以验证SII指数在临床实践中的意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb70/6370019/f3fb4928c4da/medi-98-e13788-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb70/6370019/4bcd0136462e/medi-98-e13788-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb70/6370019/9379460d50e0/medi-98-e13788-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb70/6370019/faeeabf8b2a7/medi-98-e13788-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb70/6370019/6b35ace18c07/medi-98-e13788-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb70/6370019/f3fb4928c4da/medi-98-e13788-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb70/6370019/4bcd0136462e/medi-98-e13788-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb70/6370019/9379460d50e0/medi-98-e13788-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb70/6370019/faeeabf8b2a7/medi-98-e13788-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb70/6370019/6b35ace18c07/medi-98-e13788-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb70/6370019/f3fb4928c4da/medi-98-e13788-g007.jpg

相似文献

1
Systemic immune-inflammation index is a promising noninvasive marker to predict survival of lung cancer: A meta-analysis.全身免疫炎症指数是预测肺癌生存率的一种有前景的非侵入性标志物:一项荟萃分析。
Medicine (Baltimore). 2019 Jan;98(3):e13788. doi: 10.1097/MD.0000000000013788.
2
Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.系统免疫炎症指数、中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值可预测纳武利尤单抗治疗转移性非小细胞肺癌患者的临床结局。
J Clin Lab Anal. 2019 Oct;33(8):e22964. doi: 10.1002/jcla.22964. Epub 2019 Jul 8.
3
Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.系统免疫炎症指数预测 III 期非小细胞肺癌患者的放化疗耐药和不良预后。
J Transl Med. 2017 Oct 31;15(1):221. doi: 10.1186/s12967-017-1326-1.
4
Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non-small cell lung cancer.全身性免疫炎症指数(SII)可用于预测手术切除的非小细胞肺癌患者的生存结局。
Thorac Cancer. 2019 Apr;10(4):761-768. doi: 10.1111/1759-7714.12995. Epub 2019 Feb 7.
5
Systemic immune-inflammation index changes predict outcome in stage III non-small-cell lung cancer patients treated with concurrent chemoradiotherapy.系统免疫炎症指数变化可预测接受同期放化疗的 III 期非小细胞肺癌患者的结局。
Future Oncol. 2021 Jun;17(17):2141-2149. doi: 10.2217/fon-2020-1272. Epub 2021 Feb 26.
6
Preoperative systemic immune-inflammation index predicts prognosis and guides clinical treatment in patients with non-small cell lung cancer.术前全身免疫炎症指数可预测非小细胞肺癌患者的预后并指导临床治疗。
Biosci Rep. 2020 Mar 27;40(3). doi: 10.1042/BSR20200352.
7
High systemic immune-inflammation index is a predictor of poor prognosis in patients with nonsmall cell lung cancer and bone metastasis.高全身性免疫炎症指数是预测非小细胞肺癌伴骨转移患者预后不良的指标。
J Cancer Res Ther. 2021 Dec;17(7):1636-1642. doi: 10.4103/jcrt.jcrt_176_21.
8
Systemic Immune-inflammation Index Predicts Survival of Patients After Curative Resection for Non-small Cell Lung Cancer.全身免疫炎症指数可预测非小细胞肺癌根治性切除术后患者的生存率。
In Vivo. 2018 May-Jun;32(3):663-667. doi: 10.21873/invivo.11291.
9
The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy.系统免疫炎症指数在预测接受立体定向放疗的非小细胞肺癌脑转移患者生存结局中的价值。
Mediators Inflamm. 2021 Oct 29;2021:2910892. doi: 10.1155/2021/2910892. eCollection 2021.
10
High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs.高全身免疫炎症指数预示着接受表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)治疗的晚期肺腺癌患者预后不良。
Medicine (Baltimore). 2019 Aug;98(33):e16875. doi: 10.1097/MD.0000000000016875.

引用本文的文献

1
A Machine Learning Model Integrating Preoperative Blood-Based Indices for Early and Noninvasive Detection of Endometrial Cancer.一种整合术前血液指标的机器学习模型用于子宫内膜癌的早期无创检测
J Inflamm Res. 2025 Aug 12;18:10873-10884. doi: 10.2147/JIR.S530974. eCollection 2025.
2
Lymphadenectomy in upper tract urothelial carcinoma: Clinical insights and controversies (Review).上尿路尿路上皮癌的淋巴结清扫术:临床见解与争议(综述)
Oncol Rep. 2025 Nov;54(5). doi: 10.3892/or.2025.8970. Epub 2025 Aug 14.
3
Machine learning and discriminant analysis model for predicting benign and malignant pulmonary nodules.

本文引用的文献

1
Preoperative increased systemic immune-inflammation index predicts poor prognosis in patients with operable non-small cell lung cancer.术前全身性免疫炎症指数升高可预测可手术非小细胞肺癌患者的预后不良。
Clin Chim Acta. 2018 Sep;484:272-277. doi: 10.1016/j.cca.2018.05.059. Epub 2018 May 31.
2
Advances in antibody therapeutics targeting small-cell lung cancer.靶向小细胞肺癌的抗体疗法进展
Adv Clin Exp Med. 2018 Sep;27(9):1317-1323. doi: 10.17219/acem/70159.
3
Platelets, autotaxin and lysophosphatidic acid signalling: win-win factors for cancer metastasis.
用于预测肺结节良恶性的机器学习与判别分析模型
BMC Med Inform Decis Mak. 2025 Jul 18;25(1):272. doi: 10.1186/s12911-025-03067-8.
4
The Mesothelioma Systemic Inflammation Score Is Independently Associated with Overall Survival and Predicts Benefit of Multimodality Treatment in Pleural Mesothelioma.间皮瘤全身炎症评分与总生存期独立相关,并可预测胸膜间皮瘤多模式治疗的获益情况。
Cancers (Basel). 2025 Apr 20;17(8):1371. doi: 10.3390/cancers17081371.
5
Correlation Between Systemic Immune Inflammatory Index and Suicidal Attempt in Patients with First-Episode Untreated Depression and its Risk Factors.首发未治疗抑郁症患者全身免疫炎症指数与自杀未遂的相关性及其危险因素
Neuropsychiatr Dis Treat. 2025 Apr 11;21:827-839. doi: 10.2147/NDT.S512964. eCollection 2025.
6
Peripheral inflammatory factors as prognostic predictors for first-line PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer.外周炎症因子作为晚期非小细胞肺癌一线PD-1/PD-L1抑制剂预后预测指标
Sci Rep. 2025 Apr 2;15(1):11206. doi: 10.1038/s41598-024-84469-y.
7
Prognostic and Therapeutic Implications of Alamandine Receptor MrgD Expression in Clear Cell Renal Cell Carcinoma with Development of Metastatic Disease.在伴有转移性疾病发生的透明细胞肾细胞癌中,丙氨酸受体MrgD表达的预后及治疗意义
Biomolecules. 2025 Mar 7;15(3):387. doi: 10.3390/biom15030387.
8
Diaphragm excursion difference as an adjunct predictor marker of postoperative pulmonary complications in video-assisted thoracoscopic surgery: a prospective, observational study.膈肌移动度差异作为电视辅助胸腔镜手术术后肺部并发症的辅助预测指标:一项前瞻性观察研究。
J Thorac Dis. 2025 Feb 28;17(2):908-920. doi: 10.21037/jtd-24-1454. Epub 2025 Feb 21.
9
Neutrophil-to-lymphocyte, platelet-to-lymphocyte ratios and systemic immune-inflammation index in patients with post-traumatic stress disorder.创伤后应激障碍患者的中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值及全身免疫炎症指数
BMC Psychiatry. 2024 Dec 31;24(1):966. doi: 10.1186/s12888-024-06439-y.
10
The Prognostic Value of Systemic Immune-Inflammation Index Supporting Age-Adjusted Charlson Comorbidity Index in Non-Small Cell Lung Cancer Patients with First-Line Platinum-Based Chemotherapy.全身免疫炎症指数在支持一线铂类化疗的非小细胞肺癌患者中对年龄校正Charlson合并症指数的预后价值
Int J Gen Med. 2024 Dec 6;17:5837-5848. doi: 10.2147/IJGM.S486674. eCollection 2024.
血小板、自分泌酶和溶血磷脂酸信号:癌症转移的双赢因素。
Br J Pharmacol. 2018 Aug;175(15):3100-3110. doi: 10.1111/bph.14362. Epub 2018 Jun 25.
4
Prognostic value of systemic immune-inflammation index in patients with advanced non-small-cell lung cancer.系统免疫炎症指数在晚期非小细胞肺癌患者中的预后价值。
Future Oncol. 2018 Oct;14(25):2643-2650. doi: 10.2217/fon-2018-0285. Epub 2018 May 11.
5
Systemic Immune-inflammation Index Predicts Survival of Patients After Curative Resection for Non-small Cell Lung Cancer.全身免疫炎症指数可预测非小细胞肺癌根治性切除术后患者的生存率。
In Vivo. 2018 May-Jun;32(3):663-667. doi: 10.21873/invivo.11291.
6
The Neutrophil to Lymphocyte Ratio May Predict Benefit from Chemotherapy in Lung Cancer.中性粒细胞与淋巴细胞比值可能预测肺癌化疗疗效。
Cell Physiol Biochem. 2018;46(4):1595-1605. doi: 10.1159/000489207. Epub 2018 Apr 20.
7
Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database.白人和黑人男性的中性粒细胞、淋巴细胞和血小板计数与前列腺癌预后风险:来自SEARCH数据库的结果
Cancer Causes Control. 2018 Jun;29(6):581-588. doi: 10.1007/s10552-018-1031-2. Epub 2018 Apr 17.
8
Re(de)fining Innate Lymphocyte Lineages in the Face of Cancer.在癌症面前重新定义固有淋巴细胞谱系。
Cancer Immunol Res. 2018 Apr;6(4):372-377. doi: 10.1158/2326-6066.CIR-17-0440.
9
Lymphocyte to Monocyte Ratio and Modified Glasgow Prognostic Score Predict Prognosis of Lung Adenocarcinoma Without Driver Mutation.淋巴细胞与单核细胞比值及改良格拉斯哥预后评分预测无驱动基因突变的肺腺癌预后
World J Oncol. 2018 Feb;9(1):13-20. doi: 10.14740/wjon1084w. Epub 2018 Mar 8.
10
Systemic immune-inflammation index in germ-cell tumours: search for a biological prognostic biomarker.生殖细胞肿瘤的系统性免疫炎症指数:寻找生物预后标志物。
Br J Cancer. 2018 Mar 20;118(6):761-762. doi: 10.1038/bjc.2018.7. Epub 2018 Feb 27.